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Abstract
Alzheimer’s disease (AD) is a debilitating neurodegenerative disorder, which currently
affects nearly 5.5 million people in the United States alone. Clinical features often
exhibited in AD include memory loss, unusual behavior, personality changes, and
impaired cognitive function. The primary molecular hallmarks of AD include deposits of
senile plaques and neurofibrillary tangles in brain tissue. A myriad of risk factors are
associated with the disease, but this review will focus on Apolipoprotein E
polymorphisms and certain environmental factors. Understanding the role of
Apolipoprotein E in AD pathology may aid in the development of certain drug therapies
and possible cures for AD. Moreover, epigenetic mechanisms such as deoxyribonucleic
acid (DNA) methylation are equally important in understanding AD pathology.
Environmental factors may have the potential to induce the epigenetic mechanisms
associated with AD. As a result of these new findings, the focus of some AD research has
recently shifted to a preventive approach in understanding AD pathology. The
relationship between Apolipoprotein E polymorphisms and environmental factors in AD
pathology will address the importance of preventive measures that can be taken in regard
to AD.
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Contributions of Apolipoprotein E and Environmental Factors in Alzheimer’s Disease
History and Background of Alzheimer’s Disease
Alzheimer’s disease (AD), the most common form of dementia, is a progressive
neurodegenerative disorder characterized by memory loss, unusual behavior, personality
changes, and impaired cognitive function. The hallmarks of the disease include loss and
damage of neurons, intracellular protein deposits known as neurofibrillary tangles, and
extracellular protein deposits referred to as amyloid-beta plaques or senile plaques
(Parihar & Hemnani, 2004). Despite advanced imaging techniques such as positron
emission tomography (PET), functional magnetic resonance imaging (fMRI), computerassisted tomography, hydrogen magnetic resonance spectroscopy (1H MRS), and
magnetic resonance spectroscopy (MRS), a definitive diagnosis of AD can only be made
post-mortem by way of a brain autopsy, which can confirm the relationship between
clinical features and the presence of senile plaques and neurofibrillary tangles in brain
tissue (Brody, 2011; Parihar & Hemnani, 2004).
Alzheimer’s disease was first described by Alois Alzheimer, a German
neuropsychiatrist and neuropathologist. Alzheimer firmly believed that clinical work and
laboratory research, although separate disciplines, were essential to the development of
both. Taking this approach, Alzheimer showed keen interest in his patients and their
behavior as well as the examination of their brains after their death. One of Alzheimer’s
patients was Auguste Deter, a 50-year-old woman exhibiting significant cognitive decline
in the form of delirium, hallucinations, memory problems, apathy, and ultimately
muteness and unresponsiveness. Although Alzheimer was not the first to report on
amyloid plaques, he was the first to notice neurofibrillary tangles. Alzheimer first noticed
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the characteristic neurofibrillary tangles in Deter’s brain after her death. Subsequent
findings similar to Deter’s case soon became more common, and Alzheimer’s coworker,
Emil Kraepelin, considered these findings to be consistent with his own ideas on brain
psychiatry. Kraepelin soon dubbed this new illness a disease and referenced it as
Alzheimer’s disease in his next edition of Textbook of Psychiatry (Verhey, 2009).
The dawn of a newly recognized disease always feeds a heightened interest and
desire by both the medical and scientific communities to meticulously research and solve
the new problem. In the past 100 years, great measures have been taken to understand
and combat AD. The past 30 years have met significant success in AD research as many
advancements have been made in the disciplines of genetics, epigenetics, molecular
biology, and biochemistry (Alzheimer's Association, 2012). Despite the advancements
made in AD research, many people still continue to suffer from the disease.
Since the case of Auguste Deter, millions of people have been diagnosed with
AD. Worldwide, the disease has affected over 25 million people (Dalvi, 2012). In the
United States alone, nearly 5.4 million people had AD in 2012, with 5.2 million of those
people being 65 and older. These numbers are expected to rise significantly in the coming
years as the baby boomer generation ages and as technological advances allow for longer
life expectancy. It has been projected that by the year 2050, 11 million to 16 million
people in the United States will have AD, ignoring the possible development of cures for
the disease by that time. These predictions are illustrated in Figure 1. With cases of AD
on the rise, the economic impact is daunting. The cost of care is expected to rise
significantly.
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In 2012, the total cost for health care, long-term care, and hospice for patients with AD
amounted to $200 billion and is expected to reach $1.1 trillion by 2050 (Alzheimer's
Association, 2012).
AD presents in two forms, early-onset and late-onset. Individuals with early-onset
AD show symptoms before 65 years of age, while people with late-onset AD show
symptoms at 65 years or older. Late-onset AD constitutes the majority of AD cases
(Koedam et al., 2010). Symptoms progress within three domains. Cognitive symptoms
present first followed by behavioral symptoms and finally ending in functional symptoms
(Dalvi, 2012). Although symptoms vary from person to person, memory loss is typically
the first symptom that people develop. Because neuron function is impaired in regions of
the brain used for forming new memories, short-term memory function is severely
affected. Memory loss then leads to other challenges such as having difficulty in
completing familiar tasks in daily life, being confused with time and place, misplacing
items and being unable to retrace one’s steps to find those items, and having difficulty
understanding visual images and spatial relationships. Symptoms progressively become
worse as behavioral changes become more apparent. People may show drastic changes in
mood and personality and may become socially withdrawn. In the final stages, people
with AD lose functional abilities and do not recognize loved ones. Assistance must be
provided in bathing, dressing, eating and using the bathroom. Ultimately, the individual
becomes bed-ridden and becomes extremely susceptible to infection, notably pneumonia.
At this point, AD is fatal (Alzheimer's Association, 2012).
A variety of risk factors are associated with AD, age being the leading risk factor.
By the time a person reaches 65 years of age, the chances of developing AD doubles
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every 5 years thereafter. By age 90, an individual has a 35%-40% chance of having the
condition. Genes also serve as a risk factor for AD. The most well known genetic risk
factors are mutations in genes such as amyloid precursor protein (APP), presenilin-1
(PSEN-1), and presenilin-2 (PSEN-2) and the ε4 allele of apolipoprotein E (APOE)
(Welsh-Bohmer, Plassman, & Hayden, 2010). Familial and twin studies have confirmed
the large role that genetic factors play in AD. In addition to age and certain genes,
environmental factors working through epigenetic mechanisms are also thought to
contribute to AD risk (Dalvi, 2012).
Until more can be revealed about the causes of AD and the genetic and molecular
influences involved in its pathology, AD will remain insatiable in its course of robbing
societies not only economically but also relationally. The future, however, is not entirely
grim. New findings continue to be made regarding the role of genetics in AD pathology.
Moreover, how gene expression can be altered through various environmental exposures
is a promising avenue to understanding the disease more fully. Genes do not have to seal
a person’s fate. To see a glimpse of both the genetic and environmental factors involved
in AD pathology, a protein directly involved in the process known as apolipoprotein E
(ApoE) will be investigated in detail followed by an explanation of how environmental
factors alongside ApoE may influence AD pathology.
Biology of Apolipoprotein E (ApoE)
Knowing that genetics significantly contribute to the pathology of AD, scientists
have intensely studied and searched out genes thought to be associated with AD. To date,
researchers have identified over 660 genes that are suspected to be associated with AD.
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One gene in particular, accounting for up to 50% of the known genetic contribution to
AD, is known as APOE, the first gene discovered to have a correlation with late-onset
AD. Consequently, APOE has been extensively researched (Welsh-Bohmer et al., 2010).
APOE is responsible for encoding apolipoprotein E (ApoE), a protein involved in the
transport of lipids throughout the body.
Structure of Apolipoprotein E
To better understand the function of ApoE, its structure must first be understood.
The APOE gene is found on the long arm of chromosome 19 at position 13.2 and consists
of 1223 base pairs and is made of four exons. The protein product is a 34-kDa protein
consisting of 299 amino acids, which are arranged into two structural domains, an Nterminal domain and a C-terminal domain. A hinge region separates the two domains.
Four amphipathic α-helices make up the N-terminus, and of particular interest is the
fourth α-helix, whose characteristic kinks are responsible for constituting the low-density
lipoprotein (LDL) receptor-binding region of ApoE. Many basic amino acids constitute
this region of the protein and account for the evident kinks in the N-terminus. The
binding ability of ApoE in the N-terminus is heavily influenced by the presence of many
basic amino acids (Hsieh & Chou, 2011). The C-terminal domain, made up of amino
acids ~225-299, contains the lipid binding region which is comprised of amino acids
~244-272. The amino acid sequence is crucial to the binding ability of the protein. Figure
2 illustrates the ApoE characteristics described above (Mahley, Weisgraber, & Huang,
2009).
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Function of Apolipoprotein E
Understanding the function of a protein is essential, but knowing where that
protein is made and used in the body is equally important. Primarily, the liver and brain
are responsible for synthesizing ApoE. Lesser amounts of ApoE are synthesized in the
adrenal glands and the kidneys (Elshourbagy, Liao, Mahley, & Taylor, 1985). Originally,
astrocytes, oligodendrocytes, and ependymal layer cells were the only known source of
ApoE synthesis in the brain. However, according to recent studies, neurons may produce
ApoE in small quantities when under pathophysiological stress (Xu et al., 2006).
Apolipoprotein E performs various functions, but its primary function is to
catabolize and transport triglyceride-rich lipoprotein constituents thus allowing for proper
transport and circulation of lipoproteins, fat-soluble vitamins, and cholesterol throughout
the body but primarily in the brain (Singh, Singh, & Mastana, 2002). Cholesterol, for
example, is essential for proper brain function, considering cholesterol is a component of
cellular membranes and myelin sheaths within the brain. Ultimately, synaptic integrity
and neuronal function depend heavily on cholesterol transport within the brain by way of
the contributing activities of ApoE (Pfrieger, 2003). Astrocytes hold the primary
responsibility of producing brain ApoE/lipoprotein particles. After astrocytes have
produced ApoE/lipoprotein particles, cholesterol and other lipids are delivered to neurons
to support neuronal synapses by way of interactions between ApoE receptors and ApoE
(Bu, 2012). See Figure 3 for the role of ApoE in lipid transport within the brain.
To ensure that synapse formation is carried out successfully, the following steps
must be met. First, astrocytes synthesize and secrete ApoE, which then combines with
cholesterol and other lipids to form lipoprotein particles. The assembly of ApoE and
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lipids to form lipoprotein particles is conducted by a plasma membrane transporter called
ATP-binding cassette, sub-family A (ABCA1). After lipoprotein formation, one of two
paths can be taken. The ApoE-lipoprotein particles will either bind to the neuronal ApoE
receptors known as, low-density lipoprotein receptors (LDLRs) and low-density
lipoprotein receptor-related protein 1 (LRP1), or will be transported to the cerebrospinal
fluid (CSF). Moreover, instead of going directly to neuronal ApoE receptors or to CSF,
ApoE-lipoprotein particles can be modified through a step involving recruitment of
oligodendrocyte-specific lipids and additional ApoE molecules (Bu, 2009).
It has been suggested that AD pathology is heavily influenced by compromised
cholesterol metabolism within the brain. For example, AD brains tend to have lower
levels of cholesterol in comparison to healthy brains. With this in mind, it is proposed
that the different isoforms of ApoE are responsible for compromised cholesterol
metabolism within the brain (Steinberg, 2009).
The different alleles of APOE include ɛ2, ɛ3 and ɛ4, with ɛ3 being the most
common. The ɛ3 allele is considered to be the normal form of APOE and is present
within approximately 79% of all ethnic populations (Alzheimer Research Forum, 2010).
Moreover, the ɛ3 allele is considered a protective agent against late-onset AD (Steinberg,
2009). The other alleles, ɛ2 and ɛ4 are less common and are found in 7% and 14% of the
population respectively. The ɛ2 and ɛ4 alleles are known to be the culprit of various
diseases. For example, individuals homozygous for ApoE ɛ2 are at risk for type III
hyperlipoproteinemia, whereas those homozygous for ApoE ɛ4 are prone to develop
atherosclerosis but more importantly late-onset AD (Alzheimer Research Forum, 2010).
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The residues at positions 112 and 158 in ApoE account for the structural
differences among ApoE ɛ2, ApoE ɛ3, and ApoE ɛ4. The most common isoform, ApoE
ɛ3 has a cysteine at residue 112 and an arginine at residue 158. In contrast, ApoE ɛ2 has
cysteines at both positions resulting in less binding ability of the protein. Similarly, ApoE
ɛ4 has arginines at both positions thus affecting the proper function of ApoE
(Ghebranious, Ivacic, Mallum, & Dokken, 2005). Essentially, because the isoforms
exhibit different amino acid sequences, the functions of these isoforms will be altered.
Again, isoforms ɛ2 and ɛ4 are considered abnormal and thus are incapable of carrying out
the desired activity of the protein (Mahley et al., 2009). With pathology in mind, the main
residues of concern include the residues associated with the N-terminus (1-191) and the
C-terminus (225-299), residue 112 and residue 158. The identity of these residues
ultimately affects the structure and function of the protein. Figure 2 depicts the basic
structure of ApoE, noting key residues associated with the isoforms of the protein (Hsieh
& Chou, 2011).
Role of Apolipoprotein E in APP processing and AD Etiology
As mentioned earlier, the ɛ2 and ɛ4 isoforms of ApoE account for a heightened
predisposition to late-onset AD. Although many factors contribute to the pathology of the
disease and various hypotheses regarding AD pathology have been proposed, the
Amyloid Cascade Hypothesis is perhaps the most widely accepted view of AD
pathology. The foundation of this pathological hypothesis highlights the two main
pathological hallmarks associated with AD. These hallmarks include intracellular
neurofibrillary tangles and extracellular amyloid plaques, both of which are found in the
brain parenchyma (Potter & Wisniewski, 2012).
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Vast amounts of research have been devoted to understanding the role of amyloid
plaques in AD and how these plaques are processed from the amyloid precursor protein
(APP). Essentially, the mechanism in which APP is processed undoubtedly serves a
significant role in AD pathology. The production of amyloid plaques in the brain is often
due to mutations within the APP and PSEN genes. However, new evidence suggests that
the Amyloid Cascade Hypothesis would not be complete without considering the
influence of amyloid-associated inflammatory proteins such as α1-antichymotrypsin
(ACT) and ApoE. Both ACT and ApoE influence amyloid formation by assisting other
proteins in forming the plaques. In a sense, ACT and ApoE serve as pathological
chaperones (Potter & Wisniewski, 2012).
Before elaborating on how ApoE and other amyloid-associated inflammatory
proteins play a role in amyloid formation, a basic overview of APP processing should be
discussed. Two basic pathways exist in APP processing. One path results in the
production of Aβ peptides while the other path does not produce Aβ peptides (O’Brien &
Wong, 2011).
First, APP is sorted within the endoplasmic reticulum and golgi apparatus. Once
sorting has been achieved in the golgi apparatus, APP is delivered to the axon, where it is
transported by fast axonal transport to synaptic terminals. The next few steps in APP
processing occur at the cell surface and in the trans golgi network (TGN). By way of
clathrin-associated vesicles, APP is transported from the TGN to either the cell surface or
directly to an endosomal compartment (O’Brien & Wong, 2011).
Mechanisms at the cell surface, although occurring at rapid paces, are extremely
important in APP processing. Once at the cell surface, APP is proteolyzed by α-secretase
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and subsequently by γ-secretase. This form of proteolysis does not generate Aβ.
Proteolysis of APP by α-secretase and γ-secretase is not the only means of processing
APP once it reaches the cell surface. Clathrin-coated pits can also reinternalize APP into
an endosomal compartment containing β-secretase and γ-secretase, both of which act as
proteases. If γ-secretase proteolyzes APP, Aβ is produced. The Aβ peptide is either
subjected to vesicle recycling and ultimately dumped into the extracellular space, or will
simply be degraded by the action of lysosomes. Whether APP will be proteolyzed by αsecretase or will be internalized by endosomes remains unclear. The final step to the APP
processing cycle entails retromers, which influence communication between endosomal
compartments and the TGN (O’Brien & Wong, 2011). See Figure 4 for APP processing
and trafficking.
As stated before, ApoE and other amyloid-associated inflammatory proteins
contribute significantly to AD pathology in the context of amyloid formation and
inflammation via APP processing, but the main question to be answered is whether the
plaques and inflammation actually contribute to AD or are merely pathological features
of AD. In other words, do amyloid plaques and inflammation cause the disease, or does
the disease promote inflammation and amyloid plaque formation? In an attempt to answer
this question, research led by Potter and Wisniewski (2012) focused on the influence of
ACT and ApoE in plaque formation. The main proposition made by Potter and
Wisniewski was that ACT and/or ApoE stimulate the production of amyloid plaques.
More specifically, the research done by Potter and Wisniewski revealed that the
formation of amyloid plaques, stimulated by ACT and/or ApoE, is heavily dependent on
dose size and isoform type.
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The ApoE isoform most responsible for promoting plaque formation is ApoE ɛ4. In
contrast, ApoE ɛ2 acts as an inhibitor in the process of plaque formation (Potter &
Wisniewski, 2012).
One study in particular, led by Manelli and colleagues (2007), helped confirm that
ApoE and other inflammatory proteins are heavily involved in the amyloid cascade.
Manelli and colleagues (2007) demonstrated in their research that Aβ neurotoxicity
significantly increased in the presence of ApoE ɛ4 as compared to ApoE ɛ2 or ɛ3. Based
off of these findings, Manelli and colleagues confirmed that ApoE ɛ4 constitutes a
negative gain of function but more importantly plays a significant role in the amyloid
cascade mechanism. Considering ApoE is an integral component of the amyloid cascade,
the absence of ApoE would halt the cascade at the harmless point of Aβ monomers.
Essentially, AD would be nonexistent without the action of ApoE in the amyloid cascade
(Potter & Wisniewski, 2012).
Despite coming across as a completely different function in relation to AD
pathology, ApoE also acts as an agent in Aβ clearance. Rather than being viewed as a
destructive agent in the case of contributing to plaque formation, ApoE in the context of
Aβ clearance serves as a protective agent. When speaking of ApoE in relation to Aβ
clearance, the ɛ2 and ɛ3 isoforms are more protective than the ɛ4 isoform, which yet
again confirms that the ɛ4 isoform increases the risk of AD. The protective qualities of
ApoE were confirmed by further experiments done by Potter and Wisniewski using APP
transgenic mice carrying a second transgene expressing one or another human ApoE
isoform. The human ApoE transgene did in fact inhibit the production of amyloid
deposits confirming the protective qualities of ApoE. However, amyloid did happen to
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develop in the mice with the ApoE ɛ4 isoform. This isoform ultimately caused plaque
accumulation to occur earlier and more extensively. From these findings, Potter and
Wisniewski assumed that human ApoE possibly serves as an inhibitor in the clearance of
Aβ plaques, with the ɛ4 isoform exhibiting the strongest inhibition (Potter & Wisniewski,
2012).
With a basic understanding of two functions that ApoE serves in the amyloid
cascade, a more detailed explanation of the actual amyloid cascade mechanism with an
emphasis placed on the exact role of ApoE in the mechanism is worth mentioning.
Amyloid precursor protein serves as the starting point in the production of Aβ plaques.
However, the production of amyloid plaques is not always the final outcome of APP
processing. The final outcome of APP depends on which proteins are interacting in the
cascade mechanism. Essentially, as APP goes through the processing cascade as
described in brief earlier, ApoE eventually participates in the process in its ability to bind
Aβ (O'Brien & Wong, 2011).
ApoE is involved in the secretory pathway of APP processing and enters the
pathway once the cell has internalized APP by the action of clathrin-mediated proteins.
Once the cell has internalized APP, APP becomes a part of an early endosome with the
assistance of ApoE and LRP1. Interestingly, amyloidogenic or non-amyloidogenic
processing can occur at this point. The type of processing that will ensue depends
primarily on which ApoE receptors are directly involved in the process. Specifically,
ApoE receptor 2 allows for APP retention at the cell surface thus promoting nonamyloidogenic processing. In contrast, in the presence of ApoE ɛ4 and LRP1,
amyloidogenic processing will ensue ultimately resulting in intraneuronal Aβ
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accumulation. Moreover, research has shown that if APP is overexpressed in neuronal
cells, ApoE ɛ4 will increase the production of Aβ. Keeping in mind the combined actions
of ApoE ɛ4 and LRP1 in APP processing, one can further understand the reasoning
behind the idea that ApoE ɛ4 stimulates plaque formation (Bu, 2009).
After reaching the early endosome stage, further APP processing is carried out by
β-secretase and γ-secretase. Although either non-amyloidogenic or amyloidogenic
processing can occur based on which ApoE receptors are involved, the type of proteases
at work in the process also have a profound effect on the end result of APP processing.
Both the non-amyloidogenic and amyloidogenic pathways and how α-, β-, and γsecretases are involved in these pathways are clearly illustrated in Figure 5 (Wilquet &
Strooper, 2004). In the non-amyloidogenic pathway, α-secretase first cleaves
membranous APP producing APPsα. Next, γ-secretase cleaves the α-carboxy terminal
fragment of APPsα generating a p3 peptide and APP intracellular domain (AICD). In the
amyloidogenic pathway, β-secretase is used in place of α-secretase thus resulting in the
production of APPsβ and membrane-anchored β-carboxy terminal fragment. Next, γsecretase cleaves the membrane bound β-carboxy terminal fragment thus generating Aβ
and AICD (Wilquet & Strooper, 2004). The generated Aβ then accumulates
intraneuronally (Bu, 2009).
As mentioned earlier, ApoE acts not only in mediating APP processing but also in
mediating Aβ clearance. Despite aggregation of Aβ in the brain, there is opportunity for
Aβ to be cleared. Two pathways of Aβ clearance have been identified, both of which are
depicted in Figure 6. The first pathway is receptor-mediated clearance and involves the
combined effects of microglia, astrocytes, and neurons within the interstitial fluid
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drainage pathway or the blood-brain barrier (BBB). ApoE also contributes significantly
to this pathway. ApoE can elicit good or bad outcomes to Aβ clearance depending on
which isoform serves as the mediator in the process. For example, isoforms ɛ2 and ɛ3
bind Aβ directly and have relatively high binding affinity for Aβ. The resulting ɛ2- and
ɛ3-Aβ complexes are then transferred to the BBB where they will then be delivered to
lysosomes to be degraded or to be transcytosed into the plasma for final clearance. In
contrast, ApoE ɛ4 fails to successfully clear Aβ because it has very poor binding affinity
for Aβ. Ultimately, clearance mediated by ApoE ɛ4 leads to highly toxic intraneuronal
Aβ accumulation. The other Aβ clearance pathway is executed by proteolytic
degradation. Various enzymes produced by neurons or glia act directly in proteolytic
degradation, but ApoE ɛ4 reduces the expression of these enzymes thus affecting proper
clearance of Aβ. Recognizing that ApoE has the potential to bind Aβ with high affinity, it
is clearly demonstrated that Aβ essentially distracts ApoE from performing its duties in
brain lipid metabolism (Bu, 2009).
Apolipoprotein E as a Therapeutic Target
To date, only five drugs are FDA approved to treat AD. These drugs include
memantine and acetylcholinesterase inhibitors, tacrine, donepezil, rivastigmine and
galantamine. These drugs improve overall cognition in people with AD but are not
capable of slowing the progression of AD. Moreover, these drugs are of no value to those
in advanced stages of AD (Fenili & McLaurin, 2005). In a sense, the worst damage has
already been done, and the approved drugs on the market have minimal positive results.
Developing therapies that target earlier pathological changes is greatly needed.
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Considering ApoE is directly involved in earlier critical steps in the pathology of AD,
ApoE stands as a promising therapeutic target.
Several different strategies have been proposed in developing effective
therapeutic models for AD, most of which focus on regulating ApoE expression and
function. One promising strategy is to change the structure of ApoE ɛ4 to better resemble
ApoE ɛ3 since ApoE ɛ4 is more often responsible for AD pathology. Molecules such as
GIND-25, a disulfonate, and GIND-105, a monosulfoalkyl have demonstrated the
capability of altering the structure of ApoE ɛ4 to mimic the structure of ApoE ɛ3 thus
limiting the production of Aβ plaques (Bu, 2009).
Regulating ApoE expression levels in the brain stands as a potential therapeutic
strategy as well. It has been suggested that increasing the expression of all ApoE
isoforms may slow down the progression of AD. In implementing this strategy,
consideration should be taken in that increasing ApoE ɛ4 expression could result in
harmful effects, primarily slowing down Aβ clearance. Ultimately, this approach in
managing expression levels of ApoE should be approached carefully since ApoE ɛ4 can
affect the brain in two different ways, either by loss of protection or gain of toxicity (Bu,
2009).
An additional therapeutic strategy is to take advantage of liver X receptors, which
are oxysterol receptors acting as transcription factors. Being transcription factors, liver X
receptors are responsible for upregulating ApoE in the brain, ultimately promoting
cholesterol efflux in neurons and glia. Moreover, liver X receptors act as agonists, thus
aiding in the clearance of Aβ (Bu, 2009).
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Considering ApoE is directly involved in Aβ deposition, another promising
therapeutic model could be disrupting ApoE-Aβ interaction. Disruption is possible by
implementing a synthetic Aβ peptide that resembles the ApoE-binding site on a fulllength Aβ molecule. This synthetic Aβ peptide has been tested in amyloid mouse models
and has proved to be quite successful in that it was BBB permeable and non-toxic.
Additionally, the synthetic Aβ peptide significantly reduced total brain Aβ levels and Aβ
plaques and sharpened memory performance in two amyloid mouse models (Bu, 2009).
Other possible therapeutic targets are ApoE receptors as they are heavily involved
in brain ApoE-lipoprotein metabolism and Aβ clearance. LRP1 and LDLR, specifically,
serve as promising targets for therapeutic measures considering decreased levels of LRP1
are observed in AD brains. It is possible that increasing LRP1 expression may result in
more effective Aβ clearance thus halting the progression of AD. Furthermore, finding a
way to block the interaction between APP and ApoE receptors in APP processing has a
promising outcome (Bu, 2009).
Epigenetics and Environmental Factors in Alzheimer’s Pathology
Understanding the genetic risk factors of AD, such as the role of ApoE
polymorphisms in AD pathology, is certainly a step forward in developing treatments and
other clinical interventions for the disease. However, current knowledge of how
epigenetics and environmental factors influence AD pathology heralds promising
preventive measures in warding off the disease. More remains to be known about the link
between genes and environmental factors, but recent evidence indicates that regardless of
a person’s genetic predisposition, his or her risk for AD can be substantially lowered by
lifestyle changes.
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General epigenetic mechanisms in relation to ApoE will be discussed in order to
understand how lifestyle changes can potentially prevent AD.
Epigenetic Mechanisms
Epigenetics, an emerging field of study, seeks to explain how environmental
factors have the potential to influence changes in phenotype through alterations in the
transcriptional activity of various genes (Welsh-Bohmer et al., 2010). Essentially, gene
expression is not entirely dependent on DNA sequence and can thus be modified by
certain epigenetic mechanisms. Inhibiting transcriptional access to certain genes is the
basis of epigenetic mechanisms, and some evidence shows that environmental factors
such as diet, hazardous exposures, and certain life events are involved in these epigenetic
mechanisms (Mastroeni et al., 2011). Interestingly, epigenetic modifications can occur in
two different realms. In one case, specific gene loci in specific cells can be subject to
modifications while in other cases, multiple genes in a variety of cells can be subject to
modifications. The latter case is thought to be involved in aging, the greatest risk factor
for AD (Mastroeni et al., 2011). To understand how environmental factors are translated
to epigenetic modifications of certain genes, it is best to be aware of the different types of
epigenetic mechanisms.
Epigenetic mechanisms can be subdivided into three primary categories, which
include histone modifications, DNA methylation, and RNA-related mechanisms. For the
sake of brevity, only DNA methylation will be covered in detail. First, however, a basic
overview of histone modification will be discussed, considering DNA methylation is a
form of histone modification (Mastroeni et al., 2011).
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Histones are proteins responsible for packaging and ordering DNA into
nucleosomes, the structural units of chromosomes. DNA winds around these histone
proteins like thread on a spool. Although their primary function rests in DNA packaging
and ordering, histones also play a significant role in gene regulation (Cramer &
Wolberger, 2011). The principal means by which histones influence gene regulation is
through conformational changes in protein structure of the histones. Moreover, how DNA
wraps around the histones can influence gene regulation. The transcriptional machinery
thus has altered access to the regions that have been modified by the two mechanisms
previously mentioned. Various mechanisms are known to modify histones. Such
mechanisms include acetylation, methylation, phosphorylation, ubiquitination,
sumoylation, citrullination, and adenosine diphosphate ribosylation. Of these mechanisms
histone acetylation and methylation are the most common forms of histone modification
and the most well understood mechanisms. Histone acetylation causes conformational
relaxation of the chromatin by neutralizing the histone proteins. Due to the neutralization,
the histone protein tails interact more weakly with the negatively charged phosphate
groups on the DNA. Now in a relaxed state, certain genes are more easily accessible to
transcriptional machinery and DNA methylation is now possible. In reverse, if the histone
proteins are deacetylated, the chromatin becomes more condensed, ultimately causing the
genes in that region of DNA to be inaccessible (Mastroeni et al., 2011).
DNA methylation is perhaps the most well understood epigenetic mechanism.
Interestingly, DNA methylation often acts in part with acetylation, as previously
mentioned. Due to its heavy influence in histone modification, DNA methylation can be
thought of as its own class of epigenetic mechanism despite being a form of histone
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modification (Mastroeni et al., 2011). As the name suggests, DNA methylation modifies
genome function and chromosomal stability by methylating DNA, specifically the
cytosine in CpG dinucleotides (Bollati et al., 2011). Any CpG site, whether in coding or
noncoding regions, has the potential to be methylated. Regions of DNA rich in CpG sites
are often referred to as CpG islands, and interestingly, the human genome is known to
have over 50,000 CpG islands. Furthermore, CpG shores, regions within 2 kb of CpGenriched sequences have been shown to be methylated, but in a tissue specific manner
(Mastroeni et al., 2011).
The enzymes responsible for carrying out DNA methylation include the DNA
methyltransferases, DNMT1, DNMT2, DNMT3a/b, and DNMT4. Prior to methylation,
histone acetylation must occur to allow the DNA to be accessible to methylation. With
the DNA now accessible, the enzymes are able to incorporate methyl groups into the
genome. The source of the methyl groups used in this process is methyltetrahydrofolate.
The methyl group is then transferred from S-adenosylmethionine to the cytosine in the
CpG site (Mastroeni et al., 2011). Methylation of the CpG regions is associated with gene
silencing. However, active transcription ensues if the body of the gene is methylated
(Balazs, Vernon & Hardy, 2011).
Although DNA methylation serves various functions, its primary purpose is to
alter gene expression. DNA methylation can alter gene expression by several different
mechanisms, but only three mechanisms will be mentioned here. The first mechanism in
which methylation can alter gene expression is by inducing histone modifications that are
involved in preventing transcriptional machinery from accessing a gene. Essentially,
genes that are highly methylated become repressed, and genes that are scarcely
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methylated undergo enhanced expression or overexpression. Some exceptions to this
pattern do exist. The second mechanism in which DNA methylation alters gene
expression is through methyl-CpG-binding proteins (MeCPs). For example, MeCP2
binds to methylated DNA triggering histone deacetylases to cause the chromatin to
become more condensed ultimately preventing access to certain genes. In some cases,
MeCP2 does not depend on DNA methylation or histone deacetylation to condense
chromatin. The final epigenetic mechanism involved in DNA methylation is
hydroxymethylation, which occurs when 5-methylcytosines are oxidized to 5hydroxymethylcytosines. The transformation of 5-methylcytosine to 5hydroxymethylcytosine ultimately causes certain genes to be highly restricted. Neurons
have shown to exhibit hydroxymethlation, which is thought to be a result of oxidative
damage and/or oxidative enzymes (Coppieters & Dragunow, 2011). See Figure 7 for a
brief overview of DNA methylation
Epigenetic Mechanisms in Alzheimer’s Pathology
As research continues to reveal the specifics of how histone modifications and
DNA methylation function in altering gene function and transcription, more can begin to
be explained in regard to the relationship between environmental factors and AD
pathology. Although not officially confirmed in literature, environmental factors are very
likely to be the cause of epigenetic modifications resulting in diseases ranging from
cancer to AD. Regarding DNA methylation, several studies have shown that the genomes
of people with AD tend to be hypomethylated. However, in some cases it has been
observed that certain genes, primarily nucleolar rRNA genes, are hypermethylated.
Hypermethylation of rRNA genes is thought to be a major contributor to AD pathology
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due to ribosomal deficiencies that result from the hypermethylation. In short, people with
AD tend to have altered DNA methylation patterns in comparison with healthy
individuals (Leszek, Sochocka & Gąsiorowski, 2012). As more is understood regarding
these DNA methylation patterns in normal aging brains versus AD brains, the
relationship between DNA modifications and AD pathology can be better explained
(Coppieters & Dragunow, 2011).
Equally important is the fact that DNA hypomethylation is known to be
associated with aging, the greatest risk factor for developing AD. The correlation
between aging and AD and how DNA methylation is involved in AD pathology opens up
many new prospects in understanding both the aging process and AD pathology. To
investigate this correlation, Ladd-Acosta et al., (2007) conducted a study using bisulfite
conversion. The main conclusion drawn from this study was that DNA methylation levels
at specific CpGi loci increased with increasing age (Ladd-Acosta et al., 2007).
Although DNA methylation is directly involved in tau and neurofibrillary tangle
formations and in Aβ-related mechanisms, it does have possible association with ApoE as
well. Not much research has focused on the methylation status of APOE thus far
(Mastroeni et al., 2011). However, some evidence has suggested that the APOE promoter
is poorly methylated. Interestingly, the degree of methylation does vary among the
different APOE alleles. For example, the methylation of CpG sequences are evident in
the ε4 allele but not in the ε2 or ε3 alleles (Wang, Oelze & Schumacher, 2008). In review,
the ε4 allele stands as a significant risk for developing AD.
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Interestingly, however, having the ε4 allele does not ensure the development of AD,
which begs the question of whether or not methylation status at ε4 CpG sites is altered in
ε4 carriers who end up developing AD (Mastroeni et al., 2011).
Inducing Epigenetic Changes via Environmental Factors
Much more can be said about epigenetic mechanisms, but of particular interest is
identifying certain environmental factors that may induce epigenetic mechanisms. As
mentioned before, aging is the greatest risk factor for AD and thus stands as a primary
inducing factor in epigenetic mechanisms. Aging clearly cannot be evaded and therefore
serves as a poor modifiable agent (Welsh-Bohmer et al., 2010). Other environmental
factors, however, are promising modifiable agents. Many different environmental factors
have been studied, including lead, arsenic, tobacco, education, diet, and engagement in
physical activity to name a few.
Although all of the aforementioned factors are important in epigenetic
mechanisms, the discussion here will focus on diet. A study conducted by Gu et al.
(2010) demonstrated the effects of diet on AD development. The dietary patterns of 2000
subjects were analyzed. Only 253 people developed AD, but Gu et al. confirmed that
diets rich in omega-3 and omega-6 polyunsaturated fatty acids, vitamin E, and folate,
along with limited consumption of saturated fatty acids and vitamin B12, reduced the risk
of AD. Moreover, those who ate more fruits and vegetables and less animal products
lowered their chances of developing AD. The reason that eating less meat protects against
AD is that meat contains high levels of vitamin B12, a risk factor for AD. Likewise,
eating more fruits and vegetables protects against AD because of the high levels of
vitamin C found in these foods.
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Interestingly, vitamin C has been found to decrease DNA methylation, specifically in
human embryonic stem cell lines, HES2 and HES3 (Coppieters & Dragunow, 2011).
Similar to the findings of Gu et al., Dr. Campbell (2006), author of The China
Study, has found after a twenty-seven-year laboratory program funded by the National
Institutes of Health, the American Cancer Society and the American Institute for Cancer
Research, and after four decades of biomedical research that a healthy diet, primarily a
plant-based diet, has the potential to prevent diseases such as AD. Such a diet has the
potential to prevent not only AD but also other diseases such as heart disease and
diabetes, both of which are risk factors for AD. Campbell provides several arguments that
are consistent with one another and support the notion that diet has a profound effect on
AD development. One argument rests on recent studies focusing on the prevalence of AD
in Japanese men living in Hawaii versus Japanese men living in Japan. According to this
study, The Japanese American men had much higher rates of AD than the Japanese men
living in Japan. Similarly, an additional study found that African American men living in
Indiana had significantly higher rates of dementia and AD than native Africans. A more
broad study, focusing on dietary habits in eleven different countries, found that
populations with high fat intake and low cereal and grain intake experienced higher rates
of AD. As illustrated by the previously mentioned studies, dietary habits have a profound
effect on AD pathology (Campbell & Campbell, 2006). In addition, one can gather from
these findings that the typical American diet, which is commonly high in saturated fat
and animal protein acts as a significant culprit in the development of AD.
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Concluding Remarks
Since its initial discovery by Alois Alzheimer about 100 years ago, AD has left in
its path a history of harrowing endings for many individuals and families. However,
throughout the same historical timeline, much scientific advancement has been made both
in the realm of therapeutic and preventive approaches, thus giving hope for a brighter
future. AD is a complicated disease involving a myriad of risk factors, ranging from
genetic factors to environmental factors. Of recent interest is the role ApoE plays in AD
pathology and how lipid metabolism within the brain can be drastically impaired due to
minor structural differences in ApoE. Further investigation of the direct impact that
various ApoE isoforms have on lipid and cholesterol metabolism will help elucidate the
questions yet to be answered regarding AD.
The relationship between epigenetic mechanisms and environmental factors is
equally important in the study of AD pathology, and research in this realm has gained
much more momentum in recent years. Despite the wealth of knowledge acquired in such
a short amount of time in the discipline of epigenetics, much still remains to be known
about the mechanisms involved. More is known how epigenetic mechanisms associate
with APP, but very little is known about ApoE and epigenetic mechanisms. For example,
future research could focus on the methylation status of ApoE isoforms and how this
affects AD pathology. Likewise, delineating how environmental factors such as diet have
a direct influence on the control of epigenetic mechanisms is greatly needed to advance
our knowledge about AD. Much encouragement can be taken from the fact that
environmental factors like diet play a significant role in AD pathology. Making simple
lifestyle changes may possibly be the key to warding off AD.
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Appendix

Table 1. Commonly used abbreviations.
ABCA-1

ATP-binding cassette, sub-family A

ACT

α1-antichymotrypsin

AD

Alzheimer’s disease

APOE

Apolipoprotein E

APP

Amyloid precursor protein

BBB

Blood brain barrier

DNA

Deoxyribonucleic acid

LDL

Low-density lipoprotein

LDLR

Low-density lipoprotein receptor
Low-density lipoprotein receptor-related

LRP1
protein 1
TGN

Trans golgi network
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Figure 1. Projected Numbers of People Age 65 and Over in the U.S. Population with
Alzheimer’s Disease Using the U.S. Census Bureau Estimates of Population
Growth*
*Numbers indicate middle estimates per decade. Colored area indicates low and high
estimates per decade.
(Alzheimer's Association, 2012, p. 19).
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Figure 2. The N-and-C-terminal domains of human ApoE are important in both the
structure and function of ApoE. The N-terminal domain of ApoE contains the LDL
receptor binding region while the C-terminal domain contains the lipid binding region.
Residues 112 and 158 of the E2, E3, and E4 isoforms are also important as amino acid
differences among these isoforms account for altered structure and function of ApoE
(Hsieh & Chou, 2011, p. 2).

APOE AND ENVIRONMENT

31

Figure 3. The action of ApoE is crucial to proper neuronal function. First, astrocytes
secrete ApoE, which assembles lipids and cholesterol into lipoprotein particles. ABCA1
is a plasma membrane transporter responsible for loading the lipids onto ApoE. The
newly assembled ApoE-lipoprotein particle (as depicted in the inset) can undergo
modifications before binding to receptors on neurons. Once ApoE binds to receptors on
neurons, synapse formation and repair can occur (Bu, 2009, p.8).
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Figure 4. APP trafficking in neurons is a process necessitating various components.
“Newly synthesized APP (purple) is transported from the Golgi down the axon (1) or into
a cell body endosomal compartment (2). After insertion into the cell surface, some APP is
cleaved by α-secretase (6) generating the sAPP α fragment, which diffuses away (green),
and some is reinternalized into endosomes (3), where Aβ is generated (blue). Following
proteolysis, the endosome recycles to the cell surface (4), releasing Aβ (blue) and sAPP
β. Transport from the endosomes to the Golgi prior to APP cleavage can also occur,
mediated by retromers (5)” (O'Brien & Wong, 2011, p. 191).
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Figure 5. APP can be processed by way of two pathways. Both amyloidogenic and
non-amyloidogenic pathways are possible in APP processing. β- and γ-secretase are
involved in the amyloidogenic pathway whereas α- and γ-secretase are involved in the
non-amyloidogenic pathway (Wilquet & Strooper, 2004).
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Figure 6. ApoE is also involved in Aβ clearance. The two major pathways in which
ApoE clears Aβ deposits are receptor-mediated clearance and clearance by proteolytic
degradation by endopeptidases. The different effects of ApoE E3 and E4 are noted.
LDLR-related protein 1 (LRP1) is heavily involved in the receptor-mediated clearance
pathway by binding to Aβ directly (Bu, 2009, p.7).
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Figure 7. DNA methylation is an important means for altering gene expression.
Chromatin, which is made of histones (blue cylinders) and DNA, is transcriptionally
active in a relaxed state. Chromatin transitions to the relaxed state when acetyl groups
(green blocks) are transferred from acetyl-coenzyme A to histone tails (red rods) by way
of histone acetyltransferases (HATs). DNA methylation occurs at the cytosines of
adjacent C-G/G-C dinucleotides by the action of DNA methyltransferases (DNMTs).
Methyl groups originate from methyltetrahydrofolate in conjunction with the
methionine/homocysteine cycle. CpG-methyl-binding-domain proteins (MBDs) and
methylation complex proteins (MeCps), which attract histone deacetylases (HDACs), are
involved in further inhibition of transcriptional access (Mastroeni et al., 2011, p. 1163).
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